HUE037618T2 - Gyógyszerészeti kombinációk - Google Patents

Gyógyszerészeti kombinációk

Info

Publication number
HUE037618T2
HUE037618T2 HUE13802815A HUE13802815A HUE037618T2 HU E037618 T2 HUE037618 T2 HU E037618T2 HU E13802815 A HUE13802815 A HU E13802815A HU E13802815 A HUE13802815 A HU E13802815A HU E037618 T2 HUE037618 T2 HU E037618T2
Authority
HU
Hungary
Prior art keywords
pharmaceutical combinations
pharmaceutical
combinations
Prior art date
Application number
HUE13802815A
Other languages
English (en)
Hungarian (hu)
Inventor
Dale Porter
Caroline Emery
Lujian Tan
Padmaja Yerramilli-Rao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUE037618T2 publication Critical patent/HUE037618T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE13802815A 2012-11-29 2013-11-26 Gyógyszerészeti kombinációk HUE037618T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261731174P 2012-11-29 2012-11-29
US201261731555P 2012-11-30 2012-11-30
US201361755520P 2013-01-23 2013-01-23

Publications (1)

Publication Number Publication Date
HUE037618T2 true HUE037618T2 (hu) 2018-09-28

Family

ID=49753513

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13802815A HUE037618T2 (hu) 2012-11-29 2013-11-26 Gyógyszerészeti kombinációk

Country Status (16)

Country Link
US (1) US9446043B2 (enExample)
EP (1) EP2925366B1 (enExample)
JP (1) JP6437444B2 (enExample)
CN (1) CN104812415A (enExample)
AU (1) AU2013352379B2 (enExample)
BR (1) BR112015012497B1 (enExample)
CA (1) CA2892578C (enExample)
DK (1) DK2925366T3 (enExample)
ES (1) ES2669248T3 (enExample)
HU (1) HUE037618T2 (enExample)
NZ (1) NZ708802A (enExample)
PL (1) PL2925366T3 (enExample)
RU (1) RU2674995C2 (enExample)
TR (1) TR201806682T4 (enExample)
UA (1) UA115250C2 (enExample)
WO (1) WO2014085381A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201904851D0 (en) 2019-04-05 2019-05-22 Katholieke Univ Leven Melanoma treatment
US11086278B2 (en) 2019-08-29 2021-08-10 Inventus Holdings, Llc Adaptive system monitoring using incremental regression model development
WO2022221586A1 (en) * 2021-04-15 2022-10-20 Ideaya Biosciences, Inc. Combination therapy comprising a pkc inhibitor and a mek inhibitor
WO2024044774A2 (en) * 2022-08-26 2024-02-29 Ideaya Biosciences, Inc. Methods of treating uveal melanoma with a pkc inhibitor
GB202408598D0 (en) * 2024-06-14 2024-07-31 Edvince Ab Combination treatments
GB202408599D0 (en) * 2024-06-14 2024-07-31 Vasopharma Ab Combination treatments

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489608A (en) 1989-12-21 1996-02-06 Goedecke Aktiengesellschaft Indolocarbazole derivatives and the use thereof
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
KR100340159B1 (ko) 1993-12-07 2002-11-23 일라이 릴리 앤드 캄파니 단백질키나제c억제제
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
EP1449529B1 (en) 1993-12-23 2010-01-27 Eli Lilly And Company Protein Kinase C Inhibitors
ES2122764T3 (es) 1995-11-20 1998-12-16 Lilly Co Eli Inhibidor de la proteina quinasa c.
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
US6645970B2 (en) 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
CN1253449C (zh) * 2000-11-07 2006-04-26 诺瓦提斯公司 作为蛋白激酶c抑制剂的吲哚基马来酰亚胺衍生物
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
KR100883289B1 (ko) 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2h-피리도[2,3-d]피리미딘 유도체 및 관련 화합물
TWI441637B (zh) 2005-05-18 2014-06-21 Array Biopharma Inc Mek雜環抑制劑及其使用方法
EP2246346B1 (en) 2005-07-11 2012-10-24 Novartis AG Indolylmaleimide derivatives as protein kinase inhibitors

Also Published As

Publication number Publication date
PL2925366T3 (pl) 2018-08-31
BR112015012497A2 (pt) 2017-07-11
JP2016501222A (ja) 2016-01-18
EP2925366B1 (en) 2018-02-21
US20150306101A1 (en) 2015-10-29
AU2013352379B2 (en) 2018-09-06
CA2892578A1 (en) 2014-06-05
TR201806682T4 (tr) 2018-06-21
JP6437444B2 (ja) 2018-12-12
EP2925366A1 (en) 2015-10-07
RU2015124954A (ru) 2017-01-11
BR112015012497B1 (pt) 2022-05-17
AU2013352379A1 (en) 2015-06-11
CA2892578C (en) 2021-01-12
RU2674995C2 (ru) 2018-12-14
BR112015012497A8 (pt) 2019-10-01
WO2014085381A1 (en) 2014-06-05
ES2669248T3 (es) 2018-05-24
NZ708802A (en) 2019-09-27
HK1215789A1 (en) 2016-09-15
UA115250C2 (uk) 2017-10-10
DK2925366T3 (en) 2018-06-06
CN104812415A (zh) 2015-07-29
US9446043B2 (en) 2016-09-20

Similar Documents

Publication Publication Date Title
DK3327112T3 (en) Agse-deficient stamme
DK2830816T3 (en) Hidtil ukendt coatingkoncept
ZA201501930B (en) Pharmaceutical composition
EP2935220A4 (en) PERI-carbinol
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
EP2920142A4 (en) MÉTHANOFULLERRÈNES
GB201205164D0 (en) Pharmaceutical compounds
PL2925366T3 (pl) Kombinacje farmaceutyczne
IL239512A0 (en) Pharmaceutical compounds
ZA201502987B (en) Pharmaceutical composition
GB201202027D0 (en) Pharmaceutical compounds
GB201203307D0 (en) Remvox
GB201219236D0 (en) Pharmaceutical compounds
ZA201400751B (en) Pharmaceutical composition
GB201214121D0 (en) Pharmaceutical compounds
GB201213519D0 (en) Pharmaceutical compounds
GB201203253D0 (en) Pharmaceutical compounds
GB201207264D0 (en) Medicaments
GB201207262D0 (en) Medicaments
GB201221130D0 (en) New pharmaceutical composition
AU345893S (en) Treehouse
GB201207701D0 (en) New pharmaceutical composition
GB201207628D0 (en) New pharmaceutical composition
GB201203453D0 (en) TVtidy
GB201203440D0 (en) Blu-seals